Navigation Links
InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
Date:8/30/2007

BRISBANE, Calif., Aug. 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, President and Chief Executive Officer of InterMune, will present at the Thomas Weisel Healthcare Conference in Boston on September 5, 2007 at 3:50 p.m. EDT. Mr. Welch will also present at the Bear Stearns 20th Annual Healthcare Conference in New York City on September 11, 2007 at 3 p.m. EDT.

To access a live audio webcast of the presentations, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 within the Roche research and development programs) in Phase 1a, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to anticipated future financial results and product development. All forward- looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading 'Risk Factors' in InterMune's annual report on Form 10-K filed with the SEC on March 30, 2007 (the "Form 10-K"), and other periodic reports filed with the SEC.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2019)... ... September 24, 2019 , ... ... advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, ... biopharmaceutical company focused on the development of therapies to treat central nervous ...
(Date:9/17/2019)... ... September 17, 2019 , ... Catalent, a global ... Clinical Supplies Management, Asia Pacific (APAC) will present at the upcoming 3rd Annual ... 25-26, 2019. , On Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney will ...
(Date:9/17/2019)... JUPITER, Fla. (PRWEB) , ... September 16, 2019 ... ... will broadcast Nationwide via CNBC on Saturday, September 21st @11:00am ET. Check local ... Credo Biomedical Pte. Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore ...
(Date:9/11/2019)... , ... September 10, 2019 , ... ... manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced ... be held at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. ...
Breaking Biology Technology:
(Date:9/30/2019)... (PRWEB) , ... September 30, 2019 , ... As human ... an accepted model for studying the development and diseases of the human heart, there ... activities of the progeny heart muscle cells to be clearly and easily recorded. A ...
(Date:9/25/2019)... ... September 25, 2019 , ... LeadingBiotech ... and dialogue, today announces its inaugural South CEO conference to be ... , Co-produced by Tulane University, this invitation-only meeting convenes biopharma executives to ...
(Date:9/24/2019)... ... September 24, 2019 , ... Lajollacooks4u, San Diego’s premiere ... 300 five-star reviews on the popular travel review site, TripAdvisor. , Recent reviews ... incredible food” and “unique local experience.” These sentiments have not only led the ...
Breaking Biology News(10 mins):